Biocept, Quest to provide liquid biopsy testing for lung cancer patients

Create PDF

In a separate statement, Biocept announced the launch of its CNSide cerebrospinal fluid assay, which detects cancer that has metastasized to the central nervous system. The company’s patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers.

Biocept, 858-320-8200